Life Sciences

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

Share this post:

 

Watson Health and Pfizer Inc. today announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer’s research in immuno-oncology, an approach to cancer treatment that uses the body’s immune system to help fight cancer. Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool – tapping into Watson’s machine learning, natural language processing, and other cognitive reasoning technologies to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.

More Video Stories

Watson for Drug Discovery Identifies Proteins Associated with Cardiovascular Disease

Written by Watson Health | Blog Post, Drug Discovery, Life Sciences

Heart attack and stroke are 2 of the top 10 causes of death worldwide. Identifying the proteins involved in each of them is the beginning of a journey to understanding how these diseases develop. In a novel experiment presented at the American Heart Association Scientific Sessions on November 12, 2017, and published in a supplement ...read more


Insights brief: Advancing outcomes-based contracting

Written by Watson Health | Life Sciences

In this brief, we share insights on challenges in managing outcomes-based contracts (OBCs) with health plans today and solutions to address these challenges, based on our conversations with more than a dozen life sciences companies. ...read more


Jupiter Medical Center Adopts Watson for Oncology

Written by Watson Health | Oncology & Genomics, Video

Watch the video Jupiter Medical Center in south Florida is the first U.S. regional medical center to adopt Watson for Oncology. See how Watson is providing insights to help Jupiter’s clinicians deliver evidence-based cancer care in the community setting. ...read more